Sinequa

AstraZeneca Success Story with Sinequa: Cognitive Search and Analytics Platform

As a leading biopharmaceutical company, ever wonder how you could unify your siloed data across geographies and business units to extract valuable & contextual insights? For AstraZeneca, accuracy, efficiency, and real-time results and insights were priorities to foster cooperation in R&D, drive innovation, accelerate research, catalyze drug repositioning and shorten drug time-to-market. This IDC case study report “Agile Information Discovery at …

Ajay Gautam of AstraZeneca spoke at BioPharma Mexico 2014

AstraZeneca’s Ajay Gautam on innovation in emerging markets

Last year’s BioPharma Mexico was a huge success, and we were excited to have Ajay Gautam, Executive Director and Head of Emerging Markets for AstraZeneca, as one of our speakers. Ajay has a broad experience in Big Pharma, start-ups, private equity, and venture capital with the last 7 years spent in the Emerging Markets of Latin America, Middle East, and Northern Africa. In …

Embracing big data and emerging technologies in drug safety

Which new approaches are pharma companies taking to exploit opportunities offered by big data? We’ll be answering this question and many more as we discuss big data and related innovative technologies at World Drug Safety Congress Europe. Hear from a plethora of thought leaders who will be sharing real life examples of how to develop big data programmes and social media …

BioPharma Mexico is where experts like AstraZeneca's Ajam Gautam meet to network, learn from each other, and discuss the latest biopharma strategies and technology.

AstraZeneca’s Ajay Gautam on Innovative R&D for Emerging Markets

We were glad to have Ajay Gautam, Executive Director and Head of Emerging Markets R&D at AstraZeneca, present at last year’s BioPharma Mexico. You can now download his slides from the event, where he addressed innovative R&D models for emerging markets under the main heading “How to grow the Mexican pharma industry”. View the presentation here Dr. Gautam has a …

Pfizer’s time has run out: AstraZeneca is still standing

Pfizer’s time ran out yesterday for making a formal bid to AstraZeneca, as outlined by the strict timetabling allowed for takeovers of public companies. The US drugs giant confirmed that ‘it does not intend to make an offer for AstraZeneca’. Leif Johansson, Chairman of AstraZeneca stated that in accordance with Pfizer’s confirmation to no longer pursue Astra, ‘we welcome the …

Pharma M&A Biomedical in the north

The Northern Factor and Scientific Research

Whilst the news has been dominated by Pfizer and AstraZeneca, there has been a very different story developing in the north of the UK. The Northern Health Science Alliance (NHSA) has brought together eight universities, eight NHS trusts and announced links with foreign companies, from the US and Sweden to develop new products and create ‘an internationally recognized life science …

Pharma M&A Pfizer Questioned by Government

Pfizer questioned in Parliament

Pfizer’s chief Executive Ian Read is being questioned today in Parliament over Pfizer’s potential takeover bid of AstraZeneca and its commitment to the UK.   Ian Read will be subject to hostile questions in parliament today over his proposed bid for AstraZeneca. However it wont merely be Pfizer that will be questioned, AstraZeneca’s CEO Pascal Soriot and business minister Vince …

Is ownership actually relevant? Pharma M&A Briefing

Is Ownership Actually Relevant?

As Pfizer and AstraZeneca are called before a British parliamentary committee to discuss Pfizer’s potential takeover bid, the question arises of whether ownership is relevant in the Pharma M&A world?   In the next chapter of the Pfizer AstraZeneca saga, the government has waded in to call both companies to a parliamentary committee, to discuss the situation. Whilst AstraZeneca has …

Pharma M&A Briefing: AstraZeneca rejects Pfizer

AstraZeneca rejects Pfizer’s new proposal

Pfizer increased its offer to AstraZeneca to £50 a share today, putting pressure on the UK pharmaceuticals group to open discussions, in what could lead to a deal that would create the world’s largest drugs company. However within hours AstraZeneca has once again refused to come to the table. In a statement released today, AstraZeneca have stated that the terms outlined …

Download: Exploring the global Pharma M&A market

Andrew Badrot, Founder of CMS Pharma kindly shared his thoughts on the Pharma M&A market, the challenges being faced and what companies can do to overcome the hurdles. Download a copy here The Pharma Mergers and Acquisitions market has recently seen a lot of traffic, with deals between GlaxoSmithKline and Novartis, whilst Pfizer has made overtures to AstraZeneca. With activity …